Skip to main content

Table 7 Scenario analyses of PHiD-CV 2+1 versus no vaccination or PCV13 2+1 vaccination programs in Malaysia

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Parameter Base case Scenario analysis PHiD-CV versus no vaccination (ICER) PHiD-CV versus PCV13 (cost saving [USD million]/QALYs gained)
Base case 28,497a 5.2/116
Discount rate 3% 0% 23,792a 5.7/125
Discount rate 3% 5% 31,793 4.9/110
AOM cases due to NTHi 32.3% 20.0% 30,843a 3.1/60
Adjustment factor for total AOM cases 1.0 0.7 31,371 5.2/75
Adjustment factor for total AOM cases 1.0 1.3 26,105a 5.2/157
Time horizon 10 years 100 years 10,317b 5.2/50
Indirect effects Excluded Included 21,032a 5.2/116
  1. AOM acute otitis media, ICER incremental cost-effectiveness ratio, NTHi non-typeable H. influenzae, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, QALY quality-adjusted life-year, USD United States dollars
  2. aCost-effective (<USD 30,999)
  3. bHighly cost-effective (<USD 10,333)